Log In
BCIQ
Print this Print this
 

Engineered Skin Substitute (ESS) (PermaDerm)

  Manage Alerts
Collapse Summary General Information
Company Amarantus BioScience Holdings Inc.
DescriptionAutologous tissue-engineered skin substitute
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Organ/tissue engineering
Latest Stage of DevelopmentPhase II
Standard IndicationBurns
Indication DetailsTreat pediatric severe burns; Treat severe burns in adults
Regulatory Designation U.S. - Orphan Drug (Treat severe burns in adults)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$25.0M

$3.3M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today